Ailon Pharma

Ailon Pharma is an Israeli clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic diseases, including obesity and type 2 diabetes. The company specializes in the design of multi-agonist peptides that target key metabolic pathways, specifically the GLP-1, GIP, and glucagon receptors. Its lead program, ALN-101, is a tri-agonist designed to offer enhanced efficacy in weight reduction and glucose management with a favorable safety profile. Ailon's proprietary technology aims to optimize the pharmacokinetic properties of peptides, enabling less frequent dosing and improved patient outcomes. By targeting three distinct receptors simultaneously, the company seeks to achieve metabolic benefits that surpass current standard-of-care mono- and dual-agonists.